Today it was reported that the CEO & President of Blueprint Medicines (BPMC), Jeffrey Albers, exercised options to buy 28,961 BPMC shares at $1.87 a share, for a total transaction value of $54.16K.
This recent transaction increases Jeffrey Albers’ holding in the company by 100% to a total of $1.5 million.
See today’s analyst top recommended stocks >>
Currently, Blueprint Medicines has an average volume of 441.7K.
Starting in December 2017, BPMC received 37 Buy ratings in a row. Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $99.67, reflecting a 92.1% upside. Five different firms, including Cowen & Co. and Guggenheim, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.
